CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 18 enrolled
Drug / intervention
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]drug
Likely dose
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01320293
NCT01320293N/ACompleted
CompareCT.gov

Effect of Immunomodulatory Therapy With Adalimumab on Endothelial Function in Patients With Moderate to Severe Psoriasis

University of North Carolina, Chapel Hill·interventional·Posted Mar 22, 2011·Updated Dec 26, 2016

In Brief

A clinical study evaluating Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] for Psoriasis. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. Although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial function are unknown. In this study we want to assess the cardiovascular risks factors, endothelial dysfunction and inflammatory markers before and after treatment of moderate to severe psoriasis with an FDA-approved biologic agent, adalimumab (Humira).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
CollaboratorsAbbVie

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 22, 2011
Enrollment StartMar 1, 2011
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 15.3 years ago

Interventions

Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]drug

40mg subcutaneously, every other week for 6 months